Plasminogen activator system (PA system)

The *plasminogen activator system* is a complex enzymatic cascade centered on the conversion of inactive plasminogen into active plasmin through the action of two main serine proteases—tissue-type plasminogen activator (*tPA*) and urokinase-type plasminogen activator (*uPA*)[2][3][4]. This process is tightly regulated by specific inhibitors such as *plasminogen activator inhibitor‑1* (*PAI‑1*) and *α₂-antiplasmin*, which prevent uncontrolled fibrinolysis. The primary physiological function is the dissolution of fibrin clots in blood vessels—a process known as fibrinolysis—but it also plays critical roles in extracellular matrix turnover, cell migration/invasion during wound healing or cancer metastasis, vascular remodeling after injury, regulation of inflammation, and even pathogen dissemination during infection. Therapeutically targeting this pathway has been central in treating acute thrombotic events like stroke or myocardial infarction using recombinant forms of tPA. However, manipulation carries significant risks due to potential for severe bleeding complications if not carefully controlled[3][4][5].

Other names

Plasminogen activation systemPA systemFibrinolytic system (context-dependent)tPA/uPA pathway (referring to its main components)

Activation of plasminogen to plasmin by serine proteases tPA or uPA, leading to fibrin degradation[2][3][4][5] Inhibition of the pathway by serpin family inhibitors such as PAI‑1 or PAI‑2[2][4]